Drug Name Maxalt

Bioavailability is defined as the fraction of a given drug dose that reaches the circulation in unchanged form and becomes available for systemic distribution. The larger the presystemic elimination, the smaller is the bioavailability of an orally administered drug. Drugs are designed to exert a selective influence on vital processes in order to alleviate or eliminate symptoms of disease.
The more rapid the administration, the shorter will be the time (tmax) required to reach the peak plasma level (cmax), the higher will be the cmax, and the earlier the plasma level will begin to fall again. The area under the plasma level time curve (AUC) is independent of the route of administration, provided the doses and bioavailability are the same (Dost’s law of corresponding areas).

 

In the inner ear, sensory cells of the vestibular apparatus and Corti’s organ may be injured (ototoxicity, in part irreversible). Mycobacteria are responsible for two diseases: tuberculosis, mostly caused by M. tuberculosis, and leprosy due to M. leprae. The therapeutic principle applicable to both is combined treatment with two or more drugs.
At the start of therapy, gout attacks may occur, but they can be prevented by concurrent administration of colchicine (0. 5–1. 5 mg/d). Uricosurics, such as probenecid, benzbromarone (100 mg/d), or sulfinpyrazone, promote renal excretion of uric acid. They saturate the organic acid transport system in the proximal renal tubules, making it unavailable for urate reabsorption.